Prolonged cancer control with adagrasib in patient with metastatic, KRASG12C – mutated non-small cell lung cancer (NSCLC) after sotorasib-induced hepatotoxicity: a case report.

Both sotorasib and adagrasib are approved for use in metastatic KRASG12C -mutated NSCLC after cancer progression on chemotherapy and immunotherapy. Hepatoxicity is a commonly encountered side effect of both agents, and little data exists about the safety of sequential use of these agents if hepatotoxicity is encountered. In this case report, we describe a patient who developed recurrent hepatotoxicity with sotorasib and was able to switch to adagrasib without hepatotoxicity and subsequently experienced prolonged cancer response. We also describe a previously unreported adagrasib side effect of photoinduced skin hyperpigmentation